Other news
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...
First Patient Dosed with TLX250-CDx in Italy for ccRCC
The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...
![RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013](https://radboudtranslationalmedicine.nl/cdn/42251bd5-d9e6-4107-bbd7-ac13f0c8609a/-/smart_resize/250x170/-/format/auto/-/quality/smart/citryll-cityview-combined-logo.png){kind=logo}
RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013
Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...
Interested in a collaboration?
Contact us to discuss the possibilities.